Results 71 to 80 of about 60,964 (206)

Hematological safety of olanzapine

open access: yesPsychiatria i Psychologia Kliniczna, 2016
Olanzapine is an atypical antipsychotic medication, previously expected to be safe in terms of hematological side effects and considered an alternative choice to clozapine in patients who develop hematotoxicities.
Asem A Alageel, Eisha M Gaffas
doaj   +1 more source

CMV management of patients with leukopenia after CMV high-risk kidney transplantation [PDF]

open access: yes
Background: For CMV high-risk constellations, guidelines recommend 3–6 months of prophylaxis with valganciclovir (VGCV). Management in preventing CMV primary infection in patients developing VGCV-associated leukopenia remains challenging.
Schmidt, Tina   +5 more
core   +1 more source

Frequency of Autoimmunity in Children With Autism Spectrum Disorders and Their Parents: A Cross-sectional Study [PDF]

open access: yesJournal of Pediatrics Review
Background: Autism spectrum disorder (ASD) is a neurobiological condition shaped by genetic, epigenetic, and environmental elements impacting the growing brain and marked by impaired social and emotional interaction, difficulties in learning, anxiety ...
Nasser Heravi   +3 more
doaj  

NUDT15 Polymorphism Confer Increased Susceptibility to Thiopurine-Induced Leukopenia in Patients With Autoimmune Hepatitis and Related Cirrhosis

open access: yesFrontiers in Pharmacology, 2019
The aim of this study was to investigate the influence of NUDT15 R139C and thiopurine S-methyltransferase (TPMT) on azathioprine (AZA) induced leukopenia in patients with autoimmune hepatitis (AIH) and related cirrhosis.
Xiaoli Fan   +4 more
doaj   +1 more source

In Vitro Leukoagglutination: A Rare Hematological Cause of Spurious Leukopenia [PDF]

open access: yes, 2017
Leukopenia secondary to leukocytic agglutination is caused by an ethylene diamine tetra acetic acid (EDTA) which may appear in both benign and malignant states.
Sadia Sultan, Syed Muhammad Irfan
core   +1 more source

Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer [PDF]

open access: yes, 2016
Objective To investigate the impact of hematologic toxicity and leukopenia in locally advanced cervical cancer patients undergoing neoadjuvant chemotherapy (NACT).
Francesco Raspagliesi   +27 more
core   +1 more source

Microgranular acute promyelocytic leukemia presenting with leukopenia and an unusual immunophenotype

open access: yesHematology/Oncology and Stem Cell Therapy, 2017
The microgranular variant (M3v) of acute promyelocytic leukemia (APL) is rare, and the diagnosis can be delayed due to variability in how this condition presents.
Megan H. McDonnell   +4 more
doaj   +1 more source

Immunoproteomic to analysis the pathogenicity factors in leukopenia caused by Klebsiella pneumonia bacteremia. [PDF]

open access: yes, 2014
Incidences of leukopenia caused by bacteremia have increased significantly and it is associated with prolonged hospital stay and increased cost. Immunoproteomic is a promising method to identify pathogenicity factors of different diseases. In the present
Zhongle Cheng   +4 more
core   +1 more source

Polysaccharides from the root of Angelica sinensis protect bone marrow and gastrointestinal tissues against the cytotoxicity of cyclophosphamide in mice

open access: yesInternational Journal of Medical Sciences, 2006
Cyclophosphamide (CY) is a cytostatic agent that produces systemic toxicity especially on cells with high proliferative capacity, while polysaccharides from Angelica sinensis (AP) have been shown to increase the turnover of gastrointestinal mucosal and ...
doaj  

Two Cases of Vancomycin-Induced Neutropenia

open access: yesPharmacy
(1) Background: The incidence of vancomycin-induced neutropenia in hospitalized patients is estimated to be around 2 to 8 percent Data surrounding vancomycin-induced neutropenia is limited as it is based on a small number of observational case reports ...
Kirsten Ganaja   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy